Company intelligence / Profile preview

NextCure, Inc.

Beltsville, Maryland, United Statesnextcure.com ↗

Ownership: Public · NXTC
Development stage: Phase 2

Overview

Currently conducting Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers with cohort 3 dosing underway. Previous clinical candidate NC410 (LAIR-2 fusion protein) showed some activity in combination with pembrolizumab in ovarian cancer (5 PRs in 20 patients) and colorectal cancer (3 PRs in 43 patients), but has been deprioritized in favor of LNCB74.

Therapeutic areas: OncologyImmunologyRare DiseasesNeurology
Modalities: ImmunomedicinesAntibody-Drug Conjugates (ADCs)Fusion proteinsMonoclonal antibodies
Industry: Biotech

Drug pipeline

12 assets

NC410

11 more assets in the full pipeline.

Request access →

Partnerships

LegoChem (for LNCB74)

Financials

Market cap: $29.1M
Total revenue: $0
Enterprise value: $13.3M

Beyond the preview

Go deeper on NextCure, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NextCure, Inc..

Explore the full profile